Search

Displaying results 2661 - 2670 of 4539 in total
  1. Drug

    Chromium picolinate

    go.drugbank.com/drugs/DB11255
    Approved

    Chromium ions are shown to regulate insulin by promoting glucose utilization and increasing the sensitivity of the insulin receptor [A27235].

  2. Drug

    Etifoxine

    go.drugbank.com/drugs/DB08986
    ApprovedWithdrawn

    Etifoxine is an anxiolytic and anticonvulsant drug developed by Hoechst in the 1960s. It is used in anxiety disorders and to promote peripheral nerve healing.

  3. Drug

    Fluorescein

    go.drugbank.com/drugs/DB00693
    ApprovedInvestigational

    It has been approved by FDA for use in externally applied drugs and cosmetics. (From Merck Index, 12th ed; American Medical Association Drug Evaluations; 1995, p2275)

    Products: Ak-fluor
  4. Drug

    Almotriptan

    go.drugbank.com/drugs/DB00918
    Approved

    It works by narrowing blood vessels in the brain, stopping pain signals from being sent to the brain, and stopping the release of certain natural substances that cause pain, nausea, and other symptoms

  5. Drug

    Quetiapine

    go.drugbank.com/drugs/DB01224
    ApprovedInvestigational

    Initially approved by the FDA in 1997, quetiapine is a second-generation atypical antipsychotic used in schizophrenia, major depression, and bipolar disorder.

  6. Drug

    Mersalyl

    go.drugbank.com/drugs/DB09338
    Experimental

    It is an outdated drug, and its approval has been discontinued by the FDA. Mersalyl acid is currently replaced by less toxic non-mercury containing diuretics [L1575, L1577].

  7. Drug

    Opicapone

    go.drugbank.com/drugs/DB11632
    ApprovedInvestigational

    Opicapone was approved for use by the European Commission in June 2016 [L2339] and the FDA in April 2020.[L13772] It is marketed under the brand name Ongentys as once-daily oral capsules.

  8. Drug

    HGS-TR2J

    go.drugbank.com/drugs/DB05895
    Experimental

    It is developed by Human Genome Sciences, Inc and is under Phase I of clinical trial.

  9. Drug

    Eniluracil

    go.drugbank.com/drugs/DB03516
    Investigational

    Eniluracil, which was previously under development by GlaxoSmithKline (GSK), is being developed by Adherex to enhance the therapeutic value and effectiveness of 5-fluorouracil (5-FU), one of the world’ … Eniluracil could improve 5-FU by increasing its effectiveness, reducing its side effects and/or making it orally available.

  10. Drug

    AZD 3355

    go.drugbank.com/drugs/DB05404
    Investigational

    It is developed by AstraZeneca and is currently in phase I/II trials.